All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
A phase II non-randomized, open-label trial (NCT01403636) assessed the safety and efficacy of voxtalisib (XL765/SAR245409) in patients with specific lymphoma subtypes or leukemia. Voxtalisib is a reversible inhibitor of phosphoinositide-3 kinase (PI3K) and a weak inhibitor of the mammalian target of rapamycin (mTOR). The study by Jennifer Brown, medical oncologist at the Dana-Farber Cancer Institute, Boston, was published by The Lancet Haematology online on 14 March 2018.
From the results, voxtalisib demonstrated some promising efficacy in FL but not in the other lymphoma subtypes or CLL. The authors noted that voxtalisib had an acceptable safety profile and that it might therefore warrant further its study for the FL subtype.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox